|
KMID : 0378019880310050089
|
|
New Medical Journal
1988 Volume.31 No. 5 p.89 ~ p.98
|
|
|
A Clinical Study of Unasyn^(®) (Sulbactam/Ampicillin) Therapy for Surgical Infections
|
|
김성/Kim, Song
이무혁/안우섭/배수동/조현찬/Lee, Moo-Hyouk/Ahn, Woo-Sup/Pari, Soo-Tong/Cho, Hyoun-Chan
|
|
|
Abstract
|
|
|
Sulbactam sodium is an irreversible inhibitor of serval j3-lactamases. And it displays marked synermatic effects when given along with penicillin or Cephalosporins.
Sulbactam/Ampicillin is known to be effective in acute sustemic or localized infections cause by Ampicillin-resistant organisms. So we tried to evaluate the clinical and bacteriological efficacy of S bactam/Ampicillin in various surgical infections and summarized as follows; 1. Total observed patients were 36 and 19 males, 17 females.
2. Patients were 10 cases, of Perianal Abscess 8 cases of Periappendiceal Absecess or Perforated Appendictis, 9 cases of Skin/Soft tissue Abscess or Celluiitis, 4 cases of Breast Abscess. 3 cases of Wound infection and 1 cases each of Primary peritionitis and Acute Supprative Cholangitis.
3. Unasyn, injection (Sulbactam/Ampicillin) were administered 75mg-150mg per kg weight daily for two to three days and followed oral administration with the does of 750mg-2250mg daily according t+ the severility of the target diseases.
4. The results of in-vitro sensitivity test of Sulbactam/Ampicillin were good: 87.5% for Staphyloco, cus aureus, 100% for Coagulase (-) Staphylococcus, 80% for Streptococcus spp., 76.2% for Escheri is coli, 100% for Klebsiella spp., 100% for Acinetobacter anitrautus. And Sulbactam/Ampicillin sho ed poor sensitivity results for Pseudomonas spp. (0%), and .Serratus marcescens (50%)
5. Bacteriological cure rate were observed in 78.8% of Sulbactam/Ampicillin treated patients, and clinical responses were satisfactory in 91.7% of those patients.
6. No significant adverse effects of Sulbactam/Ampicillin administration were observed.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|